Mice Naturally Produce Ozempic: Could Humans Be Next?

Medications like Ozempic and Wegovy, based on the GLP-1 formula, have been effective in both managing diabetes and aiding weight loss by regulating blood sugar and reducing hunger. However, these drugs can be quite costly and not always readily available.

What if your body could naturally produce the elements needed to control weight and blood sugar levels? Researchers at the University of Ottawa have pioneered a method that could enable plants to manufacture a substance similar to Ozempic.

Over in Japan, scientists at the University of Osaka have successfully genetically modified mice so that their livers generate exenatide, a GLP-1 drug that predates Ozempic. Remarkably, this alteration allowed the mice to maintain stable drug levels for several months, leading to weight loss, decreased appetite, and enhanced insulin sensitivity, all without a single injection.

The researchers utilized the CRISPR gene-editing technology to embed the gene for exenatide into the mice’s liver cells, resulting in continuous internal production of the drug for about 28 weeks. This innovation eliminated the need for regular pharmacy visits and the hassle of maintaining an injection schedule.

Could Human Livers Be Next in Line to Produce Their Own Diabetes Medication?

This initial experiment could revolutionize the treatment of chronic diseases. Imagine a future where, instead of periodic doses, a single gene modification could turn your body into a small-scale pharmaceutical producer.

This could potentially mean that fewer people would need to rely on injection-based medications, extending the duration of the drug’s effects and reducing medical expenses significantly.

So far, this research has only been conducted on mice, and it will be some time before human trials begin. Even after they start, translating these results to human applications could take years.

Mice are commonly used in research due to their genetic and biological similarities to humans and their rapid reproduction rate. However, results in mice don’t always directly translate to successful human treatments, despite their suitability for preliminary studies.

Moreover, reengineering a human liver to continuously produce a synthetic hormone involves complex and potentially lifelong implications. It’s crucial to thoroughly understand and mitigate these risks before such treatments can be considered safe for market release.

For now, the most reliable method for medically supervised weight loss remains weekly injections of GLP-1. However, in a few years, we might be looking at a revolutionary CRISPR modification that instructs your liver to produce its own version of Ozempic.